<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01078415</url>
  </required_header>
  <id_info>
    <org_study_id>ONC-205</org_study_id>
    <nct_id>NCT01078415</nct_id>
  </id_info>
  <brief_title>Pilot Study of Irreversible Electroporation (IRE) to Treat Early-Stage Primary Liver Cancer (HCC)</brief_title>
  <official_title>A Prospective, Multi-Center, Clinical Trial Using Irreversible Electroporation (IRE) for the Treatment of Early-Stage Hepatocellular Carcinoma (HCC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Angiodynamics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Angiodynamics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of the NanoKnife LEDC System
      for the treatment of early-stage hepatocellular carcinoma (HCC).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment efficacy as measured by modified Response Evaluation Criteria In Solid Tumors (RECIST) criteria by Computed Tomography (CT) or Magnetic Resonance (MR) imaging.</measure>
    <time_frame>30 days (+/- 3 days) post treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety using Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 criteria.</measure>
    <time_frame>Immediately post treatment to 2 years post treatment</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">26</enrollment>
  <condition>Carcinoma, Hepatocellular</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ablation with the NanoKnife Low Energy Direct Current (LEDC) System</intervention_name>
    <description>90 pulses of 70 microseconds each in duration will be administered per electrode pair.</description>
    <other_name>System also known as:</other_name>
    <other_name>* Low Energy Direct Current (LEDC) System</other_name>
    <other_name>* HVP01 Electroporation System</other_name>
    <other_name>* NanoKnife LEDC System</other_name>
    <other_name>* NanoKnife IRE System</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HCC diagnosed by positive biopsy or non-invasive criteria,

          -  not suitable for surgical resection or transplantation,

          -  have at least one, but less than or equal to 3 tumors,

          -  of the tumour(s) identified, each tumor must be ≤ 3 cm in diameter,

          -  Child-Pugh class A,

          -  Eastern Cooperative Oncology Group (ECOG) score of 0,

          -  American Society of Anaesthesiologists (ASA) score ≤ 3,

          -  a prothrombin time ratio &gt; 50%,

          -  platelet count &gt; 50x109/L,

          -  ability of patient to stop anticoagulant and anti-platelet therapy for seven days
             prior to and seven days post NanoKnife procedure,

          -  are able to comprehend and willing to sign the written informed consent form (ICF),

          -  have a life expectancy of at least 3 months.

        Exclusion Criteria:

          -  eligible for surgical treatment or transplantation for HCC,

          -  presence of vascular invasion or extrahepatic metastases,

          -  received previous treatment for HCC,

          -  HCC developed on an already transplanted liver,

          -  cardiac insufficiency, ongoing coronary artery disease or arrhythmia,

          -  any active implanted device (eg Pacemaker),

          -  women who are pregnant or women of child-bearing potential who are not using an
             acceptable method of contraception,

          -  have received treatment with an investigational agent/ procedure within 30 days prior
             to treatment with the NanoKnife™ LEDC System,

          -  are in the opinion of the Investigator unable to comply with the visit schedule and
             protocol evaluations.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Riccardo Lencioni, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pisa School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jordi Bruix, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Barcelona Clinic Liver Cancer (BCLC) Group of the University of Barcelona</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>L'institut de cancerologie Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <state>Ile-de-France</state>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Beaujon</name>
      <address>
        <city>Paris</city>
        <zip>92110</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Magdeburg AoR, Klinik fur Radiologie und Nuklearmedizin</name>
      <address>
        <city>Magdeburg</city>
        <zip>D-39120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pisa School of Medicine</name>
      <address>
        <city>Pisa</city>
        <state>Tuscany</state>
        <zip>56124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori - Fondazione Pascale</name>
      <address>
        <city>Naples</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barcelona Clinic Liver Cancer Group, Hospital Clinic i Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003 Dec 6;362(9399):1907-17. Review.</citation>
    <PMID>14667750</PMID>
  </reference>
  <reference>
    <citation>Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108.</citation>
    <PMID>15761078</PMID>
  </reference>
  <reference>
    <citation>Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodés J; EASL Panel of Experts on HCC. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001 Sep;35(3):421-30.</citation>
    <PMID>11592607</PMID>
  </reference>
  <reference>
    <citation>Bruix J, Sherman M; Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology. 2005 Nov;42(5):1208-36.</citation>
    <PMID>16250051</PMID>
  </reference>
  <reference>
    <citation>Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, Sherman M, Schwartz M, Lotze M, Talwalkar J, Gores GJ; Panel of Experts in HCC-Design Clinical Trials. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 2008 May 21;100(10):698-711. doi: 10.1093/jnci/djn134. Epub 2008 May 13. Review.</citation>
    <PMID>18477802</PMID>
  </reference>
  <reference>
    <citation>Jonas S, Bechstein WO, Steinmüller T, Herrmann M, Radke C, Berg T, Settmacher U, Neuhaus P. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology. 2001 May;33(5):1080-6.</citation>
    <PMID>11343235</PMID>
  </reference>
  <reference>
    <citation>Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001 Jun;33(6):1394-403.</citation>
    <PMID>11391528</PMID>
  </reference>
  <reference>
    <citation>Lencioni R, Cioni D, Crocetti L, Franchini C, Pina CD, Lera J, Bartolozzi C. Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation. Radiology. 2005 Mar;234(3):961-7. Epub 2005 Jan 21.</citation>
    <PMID>15665226</PMID>
  </reference>
  <reference>
    <citation>Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology. 1999 Dec;30(6):1434-40.</citation>
    <PMID>10573522</PMID>
  </reference>
  <reference>
    <citation>Yao FY, Bass NM, Nikolai B, Davern TJ, Kerlan R, Wu V, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and dropout from the waiting list. Liver Transpl. 2002 Oct;8(10):873-83.</citation>
    <PMID>12360427</PMID>
  </reference>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 26, 2010</study_first_submitted>
  <study_first_submitted_qc>March 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2010</study_first_posted>
  <last_update_submitted>November 7, 2016</last_update_submitted>
  <last_update_submitted_qc>November 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HCC</keyword>
  <keyword>Hepatocellular Carcinoma</keyword>
  <keyword>Early Stage</keyword>
  <keyword>Prospective</keyword>
  <keyword>Multicenter</keyword>
  <keyword>Irreversible Electroporation (IRE)</keyword>
  <keyword>Electroporation</keyword>
  <keyword>Low Energy Direct Current</keyword>
  <keyword>LEDC</keyword>
  <keyword>Nonthermal ablation</keyword>
  <keyword>NTIRE (nonthermal IRE)</keyword>
  <keyword>Ablation</keyword>
  <keyword>Soft Tissue</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

